Bioprocess Online Covers the Keynote “Delivering State-of-the-Art Manufacturing Facilities at an Unprecedented Pace” at the 2026 ISPE Facilities of the Future Conference
During the 2026 ISPE Facilities of the Future Conference, Victor Cruz, Senior Vice President - Corporate Engineering and Global Health, Safety, and Environmental, Eli Lilly Company, presented “Delivering State-of-the-Art Manufacturing Facilities at an Unprecedented Pace.” Cruz highlighted the strategic, logistical, and cultural challenges of building advanced good manufacturing practices (GMP) facilities at a scale rarely seen in the sector.
In the article that follows, Cruz expands on his conference presentation, offering a detailed look into Eli Lilly’s unprecedented US manufacturing expansion, which entails a more than US$50 billion-dollar capital investment for at least 12 new greenfield sites underway.
A major theme of the article is the difficulty of constructing high‑tech pharmaceutical facilities in regions that lack the infrastructure typically required for such projects. Locations like Goochland County, Virginia, and the LEAP District in Lebanon, Indiana, are not traditional industrial hubs. They often lack essential utilities such as high‑capacity electrical transmission lines, wastewater treatment capabilities, gas supply, and even broadband connectivity. Cruz explains that these gaps significantly influence site selection, cost, and schedule. When building in rural or semi‑rural areas, the distance to critical utilities can determine whether a site is viable at all. Lilly must therefore work closely with state economic development agencies, utility providers, and permitting authorities to ensure that infrastructure can be expanded quickly enough to support aggressive construction timelines.
The article also explores Lilly’s philosophy of “smart replication,” a strategy that balances the efficiency of copying proven facility designs with the need to incorporate improvements discovered during commissioning and early operations. For parenteral manufacturing sites, Lilly often orders identical equipment in bulk, such as bioreactors or fill‑finish lines, to accelerate delivery and give original equipment manufacturers (OEMs) the confidence to scale their own production capacity. For active pharmaceutical ingredient sites, the company maximizes replication of basic and detailed design across sites that share similar technologies. This approach shortens design phases, reduces commissioning and qualification time, and enables the use of digital twins and other advanced tools. However, Cruz emphasizes that replication must be thoughtful: if a design flaw or improvement opportunity emerges at one site, it should be corrected in subsequent builds, even if that reduces the percentage of direct replication.
Supply chain constraints are another major challenge. With global competition for steel, specialized equipment, and skilled labor, Lilly must diversify its supplier network and strategically select build locations to access different labor pools and material supply chains. The company also relies heavily on off‑site construction to reduce pressure on local labor markets and accelerate timelines. Early procurement is essential; Lilly places orders for critical equipment well in advance to ensure OEMs can source materials and plan production without delays. The company’s procurement and project teams also actively support suppliers by helping them resolve bottlenecks in their own supply chains.
Flexibility is a final key theme. Lilly designs its facilities not for single products but for entire future pipelines, ensuring that assets can adapt to new modalities, changing demand, and evolving regulatory expectations. Facilities are built with expansion options and with the latest available technologies, while internal “technical agendas” guide ongoing modernization efforts even before a facility is fully commissioned. This forward‑looking approach helps Lilly avoid technological lock‑in and ensures long‑term viability.
Overall, the article portrays Lilly’s US$50 billion capital program as a blend of engineering ambition, logistical complexity, and strategic foresight. Through careful site selection, smart replication, supply chain diversification, and a commitment to flexibility, the company is building a manufacturing network designed to support the next generation of therapies—and redefining what large‑scale biopharma capital delivery looks like.
Explore future ISPE Conferences
About Bioprocess Online
Bioprocess Online is part of the Life Science Connect media group. The publication provides technical information, industry knowledge, and content for the biotherapeutic community. Audiences include bioprocess engineers, scientists, bioprocessing managers, biotechnology producers, consultants, QA/QC, project managers, directors, purchasers, marketers, and those involved in biopharmaceutical supply chain or facilities management.